Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $172.4 million.

  • Relay Therapeutics' Shares Outstanding (Weighted Average) rose 28.77% to $172.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year increase of 28.77%. This contributed to the annual value of $167.4 million for FY2024, which is 35.79% up from last year.
  • As of Q3 2025, Relay Therapeutics' Shares Outstanding (Weighted Average) stood at $172.4 million, which was up 0.56% from $171.4 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Shares Outstanding (Weighted Average) peaked at $172.4 million during Q3 2025, and registered a low of $90.4 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $132.7 million (2024), whereas its average is $142.5 million.
  • Data for Relay Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 35.79% (in 2024) over the last 5 years.
  • Over the past 5 years, Relay Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $108.0 million in 2021, then grew by 11.89% to $120.9 million in 2022, then rose by 1.96% to $123.3 million in 2023, then skyrocketed by 35.79% to $167.4 million in 2024, then rose by 28.77% to $172.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $172.4 million in Q3 2025, compared to $171.4 million in Q2 2025 and $169.5 million in Q1 2025.